To the Editor: The Australian Government’s recently completed Review of anticoagulation therapies in atrial fibrillation (AF) identified that the quality of international normalised ratio (INR) control was one of a number of factors creating uncertainty regarding the cost-effectiveness of novel anticoagulants in the Australian setting.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Peter Gee for analysing project data and Daniel Owens for facilitating access to pathology data and assisting with the project.
Luke Bereznicki and Gregory Peterson have received consultancy fees from Aspen Pharmacare Australia and Boehringer Ingelheim. Luke Bereznicki has also received consultancy fees from Roche Diagnostics Australia and Sanofi Aventis, and speakers honoraria from Roche Diagnostics Australia and Boehringer Ingelheim.